The global blood plasma
derivatives market is growing mainly due to the increasing demand for plasma
derived products. According to a recent study report published by the Market
Research Future, The global blood plasma derivatives market is booming and expected
to gain prominence over the forecast period. The market is forecasted to
demonstrate a spectacular growth by 2023, surpassing its previous growth
records in terms of value with a striking CAGR during the anticipated period
(2017 – 2023).
Request Sample Copy
https://www.marketresearchfuture.com/sample_request/1325
Plasma is a fluid part of
the blood that contains blood cells, and protein responsible for blood
clotting. Plasma derivatives are obtained from specific plasma proteins by the
process of fractionation. The derivatives are then solvent detergent-treated or
heat-treated to kill certain viruses. The most common plasma derivative
includes factor IX concentrate, factor VIII concentrate, anti-inhibitor
coagulation complex (AICC), anti-thrombin III concentrate, immune globulins,
Alpha 1-Proteinase inhibitor concentrate, albumin, and anti-thrombin III
concentrate. Blood plasma derivative widely used clinically to treat various conditions
such as hemophilia A, hemophilia B, HIV, hepatitis B, hepatitis C,
thrombocytosis, and others.
Notably, rising demand for
plasma derivative based therapies is the key factor driving the Blood Plasma Derivatives Market Analysis. According to a study published in the Journal of
Blood Medicine in 2016, it is found that FIX replacement therapy which includes
plasma-derived protein are successful in the reduction of disability, and
bleeding from hemophilia B. Based on the prevalence rate, hemophilia and von
willebrand disease (VWD) are the most common bleeding disorders in the Middle
East and Africa.
Other factors such as,
rising incidence of hemophilia, huge funding for research & development,
technological advancements, and rising approval from regulatory bodies are also
fuelling the market growth. According to the Centers for Disease Control and
Prevention, it is found that Hemophilia A affects 1 in 5,000 male births i.e.
around 400 babies are born with hemophilia A every year.
Despite these drivers,
stringent reimbursement policies, safety concerns, and high cost of treatment
is expected to decline the blood plasma derivatives market growth.
Global Blood Plasma
Derivatives Market - Competitive Analysis
Grigols (Spain), Baxter
International Inc. (US), Octapharma AG (Switzerland), CSL Limited (Australia),
Kedrion S.p.A (Italy), Bain Capital, LLC (US), Biotest AG (Germany), Fusion
Healthcare (India), SK Plasma Co., Ltd. (South Korea) are some of the prominent
players at the forefront of competition in the blood plasma derivatives market
and are profiled in MRFR Analysis.
The global blood plasma
derivatives market is currently dominated by few players.
Grigols is one of them by
holding a strong share in the market. The company’s stronghold is largely
attributed to its innovative and sustainable products. Grigols aoperates in
three major divisions i.e. Bioscience, Diagnostic and Hospital. On November 17,
2017 Grigols received FDA approval for a new genetic test used to detect
alpha-1 antitrypsin deficiency. On November 11, 2013, Grifols acquired blood
transfusion testing unit of Novartis AG for USD 1.68 billion. In the year 2016,
Grifols has also acquired NAT (Nucleic Acid Testing) donor screening unit of
Hologic for USD 1,850 million.
Baxter is also one of the
leading players in blood plasma derivatives market. Baxter International Inc.,
the US based biopharmaceutical company, operates in two major segments, i.e.
Hospital Products and Renal. Baxter’s product Bebulin (Factor IX Complex) is
specifically used for the prevention, of hemorrhagic episodes in case of
hemophilia B. Bebulin may carry a risk of transmitting infectious agents, such
as viruses and, Creutzfeldt‐Jakob disease (CJD) agent.
On July 27, 2017, Baxter
International Inc. completed the acquisition of Claris Injectables Limited for
approximately USD 625 million. The main motive of acquisition is the expansion
of generic pharmaceuticals.
Access Report Details
@ https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325
NOTE: Our team of
researchers are studying Covid19 and its impact on various industry verticals
and wherever required we will be considering covid19 footprints for a better
analysis of markets and industries. Cordially get in touch for more details.
About Market Research
Future:
At Market Research Future
(MRFR), we enable our customers to unravel the complexity of various industries
through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR),
Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
Comments
Post a Comment